Please sign in to follow a disease.
Can a driving simulator spot stoned drivers? new study investigates
NCT ID NCT06255054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how cannabis affects driving by using a driving simulator. Researchers compared the driving performance of 207 adults who use cannabis daily, occasionally, or not at all. The goal was to better understand different levels of impairment and improve road safety.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help develop better ways to detect cannabis-impaired driving and improve road safety.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly lead to a new therapy. Results may not apply to all drivers or real-world conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
207 people
The number who actually took part.
- Started
-
Jun 2020
- Finished
-
Sep 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Potential participants will be recruited from the general population.
- Ages
-
25 to 55 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The following are inclusion criteria for participants to be enrolled in any of the four phases of the study: 1. Participants who are ≥21 years old and ≤55 years old 2. Participants who are able to provide written, informed consent 3. Participants with active healthcare coverage (including health insurance, Medicaid, etc.) 4. Participants who are willing to complete up to two in-person study visits (one for Phases 1 \& 2, and two for Phases 3 \& 4), including up to two urine drug screens, two alcohol breathalyzer tests, and one urine pregnancy test (if applicable) 5. Participants who agree to refrain from using non-prescription psychotropic drugs (e.g., ecstasy), hallucinogens, and synthetic cannabinoids during the study 6. Participants who agree to refrain from drinking \>3 alcoholic drinks the day prior to the data collection study visit (the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4) 7. Participants who agree to refrain from using any cannabis products for at least 8 hours prior to the data collection study visit (the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4) 8. Participants who are willing to provide and use their own cannabis product that has been procured from a licensed dispensary, is labeled with THC potency, and contains \<2% CBD (cannabis use groups only; the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4) 9. Participants who agree to have a sober driver pick them up after the data collection study visit (cannabis use groups only; the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4) 10. Participants who take at least 2 inhalations ("hits") during their typical inhalational (smoking/vaporizing) sessions, or ingest at least 5 mg of THC when they consume edible cannabis products (cannabis use groups only) 11. Participants who are willing to provide a sample of their cannabis to be independently tested for potency and terpene content (Phases 1, 3 \& 4 only) Exclusion Criteria: * The following are exclusion criteria for participants to be enrolled in any of the four phases of the study: 1. Prisoners 2. Participants who have nocturnal schedules (e.g., work night shifts) 3. Participants with a history of abuse or addiction to substances other than cannabis (e.g., prescription and non-prescription pharmaceuticals, alcohol, or illicit drugs) 4. Participants who have expressed an interest in substance abuse treatment within the 60 days prior to study enrollment 5. Participants who report consuming an average of \>3 alcoholic drinks per day in the 30 days prior to study enrollment 6. Participants with any past or current diagnosis of schizophrenia, narcolepsy, heart disease, epilepsy, or a traumatic brain injury 7. Participants who are currently experiencing untreated bipolar disorder, major depression, sleep apnea, or other uncontrolled medical conditions as determined by the investigators (e.g., hypertension) 8. Participants with a known balance or gait disorder 9. Participants with color blindness (Phase 2 only) 10. Participants who currently wear hard contact lenses for vision correction (Phase 2 only) 11. Participants who have donated 450 mL or more of blood in the two weeks prior to study enrollment 12. Participants who are pregnant or breastfeeding (female participants only) 13. Participants who report never using cannabis before in their lifetime (Phases 1 \& 2 only) 14. Participants with a history of clinically significant adverse event(s) associated with cannabis intoxication (e.g., lightheadedness, nausea, dizziness, etc., cannabis use groups only) 15. Participants with uncorrected visual acuity disorder, defined as binocular vision worse than 20/40 (Phases 2, 3 \& 4 only; determined at screening) 16. Participants with a body mass index \>40 kg/m2 (determined at screening) 17. Participants with a positive breath alcohol test (breathalyzer) at screening 18. Participants who are otherwise unsuitable for inclusion in the study, based on the opinion of the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Driving Study Lab
Denver, Colorado, 80220, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can rewards and remote coaching help people cut back on cannabis?
- Can a short tobacco break curb cannabis cravings?
- Texting teens to tame risky drinking and weed use?
- Can a blood pressure medication curb cannabis cravings?
- Could cannabis help fight diabetes? a study investigates
- A 5-session toolkit aims to curb teen cannabis use — will it work?